Live Dana-Farber Cancer Institute updates

Live Dana-Farber Cancer Institute news coverage of developments with the latest updates. Stay on top of latest Dana-Farber Cancer Institute news stories and find out what just happened, what is going on with Dana-Farber Cancer Institute. The latest real-time news updates and headlines on Dana-Farber Cancer Institute
Targeted agents, combination therapies, and clinical trial equity headline Dana-Farber research
Molecular profiling finds new high-risk subtype of pediatric liver cancer
Expanding Telehealth Possibilities: Performing Virtual Frailty Exams in Home
Performing virtual frailty exams in home
New molecular subset of pediatric liver cancer identified
Jennifer Willcox named Senior Vice President, General Counsel and Chief Governance Officer
Cell division finding could lead to new cancer treatments
Dana-Farber nurses present research and evidence-based practice projects at 2022 Oncology Nursing Society Congress
U.S. Multisociety Task Force on Colorectal Cancer releases new recommendations for harmartomatous polyposis syndrome
Johns Hopkins Medicine Researchers Awarded Nearly $8 Million from Break Through Cancer Foundation
MD Anderson receives over $10 million from Break Through Cancer to support collaborative research with leading cancer centers
Dana-Farber Cancer Institute receives $11M to intercept and cure deadly cancers
Four Leiden researchers awarded Rubicon grants
New platform optimizes selection of combination cancer therapies
Red Sox pitcher Nathan Eovaldi to continue as Jimmy Fund Captain in 2022
Ian Matthew-Clayton named Vice President and Chief Inclusion, Diversity, and Equity Officer
2022 Canada Gairdner Award given to Stuart H. Orkin, MD, researcher
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Dana-Farber Statement in Response to Conviction of RaDonda Vaught, RN
Dana-Farber Cancer Institute named 2022 LGBTQ+ Healthcare Equality Leader
Dana-Farber Cancer Institute and Lifespan renew strategic alliance agreement
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show
Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer
Drug combination reveals effectiveness in patients with recurrent ER-positive endometrial cancer
HRR mutational status prognostic of survival outcomes in biomarker analysis of NRG oncology trial for women with recurrent
Mary Tolikas named Senior Vice President and Chief Innovation Officer
Research in JNCCN measures drop in cancer detection due to Covid pandemic
Patient-centered research initiatives highlighted during Colorectal Cancer Awareness month at Dana-Farber
Tumor tissue modified viral -HPV DNA biomarker test predicts recurrence of HPV-driven oropharynx cancer after treatment
Exercise reduces anxiety during active surveillance for prostate cancer
Dana-Farber researchers to present findings at 2022 ASCO Genitourinary Cancers Symposium
Molecular treatment is able to control brain metastasis of different tumors
Most people with prior Covid infection or vaccination have T cell immune responses against Omicron variant despite low antibody
New computational tool predicts cell fates and genetic perturbations
Researchers Identify New Therapeutic Target for Hematologic Malignancies
New England Cancer Specialists to become Affiliate Member of Dana-Farber Cancer Institute
Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
Research reveals that human immune system uses ancient family of cell death proteins also in bacteria
Case of mistaken identity: Researchers unmask cellular source of Barrett’s esophagus
Study of vaccinated cancer patients with breakthrough Covid shows 13% mortality rate
Goldie Taylor named Senior Vice President, Chief Communications and Marketing Officer
Paula and Rodger Riney Foundation makes $40 million transformative grant to further multiple myeloma research
Immunotherapy combination shows significant benefit for patients with advanced melanoma
Study of fully vaccinated patients with cancer who had breakthrough Covid shows 13% mortality rate
Research of fully vaccinated patients with cancer who had breakthrough Covid reveals 13% mortality rate
FDA approval offers hope for prevention of acute graft-versus-host disease
Dana-Farber/Boston Children’s Cancer and Blood Disorders Centers launches redesigned web site
Dana-Farber /Boston Children’s Cancer and Blood Disorders Centers launches redesigned web site